Institutional members access full text with Ovid®

Share this article on:

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance

Liefferinckx, Claire MD*; Minsart, Charlotte MSc*; Toubeau, Jean-François MSc; Cremer, Anneline MD*,‡; Amininejad, Leila MD*,‡; Quertinmont, Eric*; Devière, Jacques MD*,‡; Gils, Ann PhD§; van Gossum, André MD, PhD; Franchimont, Denis MD, PhD*,‡

doi: 10.1097/MIB.0000000000001120
Original Clinical Articles

Background: Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure.

Methods: This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data. IFX trough levels (TLs) were measured by enzyme-linked immunosorbent assay. Antibodies to IFX were measured by drug-sensitive bridging assay.

Results: During follow-up, patients were defined according to treatment outcome. At week 6, median IFX TL in patients requiring a switch to another treatment due to LOR (LOR switched group) (2.32 μg/mL [0.12–19.93 μg/mL]) was lower than in patients with long-term response (long-term responders) (8.66 μg/mL [0.12–12.09 μg/mL], P = 0.007) and in patients responding to optimization (LOR optimized group) (7.28 μg/mL [0.17–14.91 μg/mL], P = 0.021). At week 2, median IFX TL was lower in the LOR switched group (5.7 μg/mL [0.15–12.09 μg/mL]) compared with the long-term responders (11.92 μg/mL [0.14–19.93 μg/mL], P = 0.041) but no significant difference was reached with the LOR optimized group (11.91 μg/mL [0.23–12.09 μg/mL], P = 0.065). In the LOR switched group, median IFX TL at induction (weeks 2 and 6) was significantly lower when patients had been previously exposed to anti–tumor necrosis factor compared with naive patients (0.91 μg/mL [0.12–4.4 μg/mL] versus 6.6 μg/mL [0.15–19.93 μg/mL], P = 0.044).

Conclusions: This study suggests that patients who do not respond to any optimization strategy have lower IFX TLs during induction at week 6. IFX TLs measured early on at induction might predict treatment failure to IFX during maintenance.

Article first published online 11 May 2017.Supplemental Digital Content is Available in the Text.

*Laboratory of Experimental Gastroenterology, Université libre de Bruxelles, Brussels, Belgium;

Electrical Power Engineering Unit, Université de Mons, Mons, Belgium;

Department of Gastroenterology, Erasme Hospital, Brussels, Belgium; and

§Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.

Address correspondence to: Denis Franchimont, MD, PhD, Department of Gastroenterology, Erasme Hospital and Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Route de Lennik 808, 1070 Bruxelles, Belgium (e-mail: Denis.franchimont@erasme.ulb.ac.be).

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).

C. Liefferinckx is supported by FNRS (Belgian National Fund of Scientific Research) and D. Franchimont is research director of FNRS.

The authors have no conflict of interest to disclose.

Received November 15, 2016

Accepted March 2, 2017

© Crohn's & Colitis Foundation
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website